New International Guidance Aims to Make Type 1 Diabetes Screening Standard Practice

Breakthrough T1D has published new international consensus guidance on screening for type 1 diabetes before it becomes symptomatic. The paper, published in Diabetologia, represents input from nearly 30 experts worldwide and addresses a critical question: who should be tested for early signs of the disease?

Early detection of type 1 diabetes involves screening blood samples to identify islet autoantibodies—markers that show the immune system is attacking insulin-producing cells. Finding these antibodies years before symptoms appear creates an opportunity to understand disease progression and explore interventions.

The new consensus recommends that type 1 diabetes screening begin in children aged 2-4 years. Children who test negative should be rescreened between ages 4-6 years and again at 10-15 years.

The guidance reflects expert agreement that catching type 1 diabetes at its earliest stages—before symptoms or the need for insulin therapy—is important for patients and their families.

When screening detects two or more persistent islet autoantibodies, it indicates a person is in stage 1 or stage 2 type 1 diabetes. Research shows that individuals with multiple autoantibodies are very likely to eventually develop stage 3 type 1 diabetes, the clinical form of the disease.

This staged framework helps doctors and researchers understand where a person is in the disease process and what monitoring or management may be appropriate.

This screening guidance builds on work Breakthrough T1D published in 2024: Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. That earlier publication explained what clinicians should do when autoantibodies are detected. The new paper addresses the step before that—determining who should be screened in the first place.

Together, these two sets of recommendations create a more complete clinical roadmap for integrating general population screening into standard practice around the world.

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.